Ankylosing Spondylitis Pipeline Drugs and Companies Insight Report (2023): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Ankylosing Spondylitis pipeline constitutes 40+ key companies continuously working towards developing 40+ Ankylosing Spondylitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Ankylosing Spondylitis Overview
Ankylosing Spondylitis, is a form of arthritis that primarily affects the spine. It causes severe inflammation of the spinal joints (Vertebrae) that can lead to chronic pain and discomfort. The hallmark feature of Ankylosing spondylitis is the involvement of sacroiliac (SI) joints during the progression of disease
"Ankylosing Spondylitis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ankylosing Spondylitis Market.

The Ankylosing Spondylitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Ankylosing Spondylitis Pipeline Report: https://www.delveinsight.com/report-store/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Ankylosing Spondylitis treatment therapies with a considerable amount of success over the years. Ankylosing Spondylitis Key players such as - Qyuns Therapeutics, Kinevant Sciences, MoonLake Immunotherapeutics, Izana Bioscience, Suzhou Zelgen Biopharmaceuticals, Sun Pharma Global, Jiangsu HengRui Mediicne, UCB, Amgen, and others, are developing therapies for the Ankylosing Spondylitis treatment
• Ankylosing Spondylitis Emerging therapies such as - QX 002N, KIN-1901, Sonelokimab, Namilumab, Jaktinib, Tildrakizumab, SHR0302, Bimekizumab, Apremilast, and others are expected to have a significant impact on the Ankylosing Spondylitis market in the coming years.
• Jiangsu HengRui initiated phase II/III, multicenter, randomized, double-blind, placebo-controlled adaptive seamless clinical study to evaluate the efficacy and safety of SHR0302 in active ankylosing spondylitis subjects
• UCB Biopharma initiated a phase III multicenter, randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of Bimekizumab in subjects with active ankylosing spondylitis. With the enrollment of 332 participants, the trial is in active, not recruiting stage and was completed by September 2022

Ankylosing Spondylitis Pipeline Therapeutics Assessment
• Ankylosing Spondylitis Assessment by Product Type
• Ankylosing Spondylitis By Stage and Product Type
• Ankylosing Spondylitis Assessment by Route of Administration
• Ankylosing Spondylitis By Stage and Route of Administration
• Ankylosing Spondylitis Assessment by Molecule Type
• Ankylosing Spondylitis by Stage and Molecule Type

DelveInsight's Ankylosing Spondylitis Report covers around 40+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Ankylosing Spondylitis Drugs Under Different Phases of Clinical Development Include:
• QX 002N: Qyuns Therapeutics
• KIN-1901: Kinevant Sciences
• Sonelokimab: MoonLake Immunotherapeutics
• Namilumab: Izana Bioscience
• Jaktinib: Suzhou Zelgen Biopharmaceuticals
• Tildrakizumab: Sun Pharma Global
• SHR0302: Jiangsu HengRui Mediicne
• Bimekizumab: UCB
• Apremilast: Amgen

Get a Free Sample PDF Report to know more about Ankylosing Spondylitis Pipeline Assessment- https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ankylosing Spondylitis Pipeline Analysis:
The Ankylosing Spondylitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Ankylosing Spondylitis treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ankylosing Spondylitis Treatment.
• Ankylosing Spondylitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ankylosing Spondylitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ankylosing Spondylitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Ankylosing Spondylitis product details are provided in the report. Download the Ankylosing Spondylitis pipeline report to learn more about the emerging Ankylosing Spondylitis therapies at:
https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ankylosing Spondylitis Pipeline Market Drivers
• Rising prevalence of Ankylosing spondylitis
• Increase in Drug Development for Ankylosing spondylitis
• Decrease quality of life

Ankylosing Spondylitis Pipeline Market Barriers
• Lack of early diagnosis of the disease
• Minimum participation of patients in physical activity
• High treatment cost and lack of caregiver

Scope of Ankylosing Spondylitis Pipeline Drug Insight
• Coverage: Global
• Key Ankylosing Spondylitis Companies: Qyuns Therapeutics, Kinevant Sciences, MoonLake Immunotherapeutics, Izana Bioscience, Suzhou Zelgen Biopharmaceuticals, Sun Pharma Global, Jiangsu HengRui Mediicne, UCB, Amgen, and others
• Key Ankylosing Spondylitis Therapies: QX 002N, KIN-1901, Sonelokimab, Namilumab, Jaktinib, Tildrakizumab, SHR0302, Bimekizumab, Apremilast, and others
• Ankylosing Spondylitis Therapeutic Assessment: Ankylosing Spondylitis current marketed and Ankylosing Spondylitis emerging therapies
• Ankylosing Spondylitis Market Dynamics: Ankylosing Spondylitis market drivers and Ankylosing Spondylitis market barriers

Request for Sample PDF Report for Ankylosing Spondylitis Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Ankylosing Spondylitis Report Introduction
2 Ankylosing Spondylitis Executive Summary
3 Ankylosing Spondylitis Overview
4 Ankylosing Spondylitis- Analytical Perspective In-depth Commercial Assessment
5 Ankylosing Spondylitis Pipeline Therapeutics
6 Ankylosing Spondylitis Late Stage Products (Phase II/III)
7 Ankylosing Spondylitis Mid Stage Products (Phase II)
8 Ankylosing Spondylitis Early Stage Products (Phase I)
9 Ankylosing Spondylitis Preclinical Stage Products
10 Ankylosing Spondylitis Therapeutics Assessment
11 Ankylosing Spondylitis Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Ankylosing Spondylitis Key Companies
14 Ankylosing Spondylitis Key Products
15 Ankylosing Spondylitis Unmet Needs
16 Ankylosing Spondylitis Market Drivers and Barriers
17 Ankylosing Spondylitis Future Perspectives and Conclusion
18 Ankylosing Spondylitis Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Ankylosing Spondylitis drugs and therapies- https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Ankylosing Spondylitis Market https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Ankylosing Spondylitis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Ankylosing Spondylitis Epidemiology https://www.delveinsight.com/report-store/ankylosing-spondylitis-bekhterevs-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Ankylosing Spondylitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Related Reports By DelveInsight -

Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.